Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
about
Targeting microRNAs as key modulators of tumor immune responseThe urgent need to recover MHC class I in cancers for effective immunotherapyCombination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancerAssessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association studyIsobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility GenesMCM7 promotes cancer progression through cyclin D1-dependent signaling and serves as a prognostic marker for patients with hepatocellular carcinoma.Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.[pemetrexed + sildenafil], via autophagy-dependent HDAC down-regulation, enhances the immunotherapy response of NSCLC cells.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacyHistone deacetylase inhibitors as immunomodulators in cancer therapeutics.Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAsSplicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression.Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes.Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.MiR-17-92 cluster promotes hepatocarcinogenesis.Cytokeratin 18-associated Histone 3 Modulation in Hepatocellular Carcinoma: A Mini Review.RNAi-mediated knockdown of MCM7 gene on CML cells and its therapeutic potential for leukemia.MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cellsEvaluation of intracavitary administration of curcumin for the treatment of sarcomatoid mesothelioma.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.Resveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway.HDAC inhibitors enhance the immunotherapy response of melanoma cells.SIRT1 promotes tumor-like invasion of fibroblast-like synoviocytes in rheumatoid arthritis via targeting TIMP1.Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands?Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis.HDAC Inhibition Improves the Sarcoendoplasmic Reticulum Ca2+-ATPase Activity in Cardiac Myocytes.MicroRNAs in the Diagnosis and Treatment of Cancer.Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects.microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells.Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a reviewING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid
P2860
Q26746972-38F45FEB-FB41-4A23-A5AC-0AC101E6C98AQ26770165-4A1B5DE6-7058-44E1-8F9C-D08C8BFB507EQ33439523-81B0246C-7EFD-4DD6-85F3-636F69BE14B8Q33815894-6E9C68F9-22C6-427A-BB29-1F0FADA73341Q35845089-43D0A03B-BFF8-4D7A-943E-E0BD56452A56Q36211604-865FDD86-1B2D-4AED-8AB9-EFA79AD8E43CQ37545100-154B62C1-675F-4CDD-B6E2-AF0350E43C76Q37734489-3B1D2988-47E4-46C7-B6AB-3050B823146FQ37745098-F0041F0E-7B25-4CB3-AF4E-EEC77B3C2E72Q38527482-B812E40B-9066-45F4-BC79-CF04B658924FQ38572855-61181578-CDD1-4B99-9D3B-00B9DF4826CEQ38622540-43E41E97-07E8-45C3-B2F7-3DE3FCC6C0A5Q38749824-97488EDF-7A35-416C-BB3D-142F676E18B1Q38763747-0B99F783-4A1B-4BA8-9E8B-0E4E36E54989Q38777547-650C3C82-36AA-4A0B-B984-87E5E37EF6CBQ38799990-86DDC84F-A906-4604-A898-0593C3E8288DQ38802155-0F61956C-2A96-46D8-92FE-33DE18E63BE2Q38962024-7DE8AC5C-4BD0-4708-8FDD-06805D6B5688Q39061756-0FA5BFEF-3A37-494F-9DE5-3B92CA1B4E9FQ39396613-D8CEB82D-4798-455E-A2FB-4A612BACF55DQ40393432-AA3AD3CC-34B4-482B-974A-787C76C9F7C1Q41169679-2FA2BC6A-2BC8-4DD1-9540-F2F49F2C250DQ41340663-F601EF94-682F-470E-A266-738F5219E015Q42042886-68363CC5-67C9-4912-8C03-21268BEE7B65Q42371577-C03BF1F9-96BE-44FF-B655-272B263BCBEBQ45072959-781754CC-2382-4F17-AEF6-CC0E8B3A2C41Q47097862-020A44B5-5817-4C6B-A678-78FAC4E93DAFQ47110491-9420DAA8-4E0E-4C6B-8821-45EC7A443C27Q47788129-58A24158-256D-4C58-8F67-DDF7006D45F1Q48134207-DFE4C204-D78B-41AB-91A7-710D881C168BQ50067809-80154D1E-B8B8-443D-BEFB-E635C5B3DB16Q50276385-7B6A99EA-5BC0-4A60-87FF-AFD6E0BCCB27Q50976179-650DE7EC-0618-4E92-AFC9-EE5D75D1EA90Q58755253-49C09A15-9D14-4217-A366-2DC140928B55Q58792092-B66EBEDC-AAD7-46A8-96FF-BCB8D0AF1538
P2860
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Histone deacetylase inhibitor ...... e MICA expression in hepatoma.
@ast
Histone deacetylase inhibitor ...... e MICA expression in hepatoma.
@en
type
label
Histone deacetylase inhibitor ...... e MICA expression in hepatoma.
@ast
Histone deacetylase inhibitor ...... e MICA expression in hepatoma.
@en
prefLabel
Histone deacetylase inhibitor ...... e MICA expression in hepatoma.
@ast
Histone deacetylase inhibitor ...... e MICA expression in hepatoma.
@en
P2093
P2860
P356
P1476
Histone deacetylase inhibitor ...... te MICA expression in hepatoma
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2014.547
P407
P50
P577
2014-11-13T00:00:00Z